Pharma Stocks: 5 Biggest Companies in 2024
The pharmaceutical industry is a major player in the life science sector, responsible for developing and manufacturing the majority of…
1,870€
2,19%
Echtzeit-Aktienkurs Johnson Service Group PLC
Bid:
Ask:
Nachrichten zur Johnson Service Group PLC Aktie
Is Johnson & Johnson a Good Dividend Stock to Buy Now? @themotleyfool #stocks $JNJ
The healthcare conglomerate has been raising its dividend payout since Kennedy was president, but there have been some recent changes.…
[Latest] Global Medical Implant Market Size/Share Worth USD 203.6 Billion by 2032 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Johnson & Johnson: Medtech-Momentum & GLP-Risiko am Horizont - Aktienanalyse
Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI),…
Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments
…
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson
These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns?…
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen.…
Better Dividend Stock to Buy Now: Johnson & Johnson vs. Verizon
Both recently reported results from the fourth quarter of 2023 and their performances could hardly look more different.…
Better Dividend Stock to Buy Now: Johnson & Johnson vs. Verizon @themotleyfool #stocks $VZ $JNJ
Both recently reported results from the fourth quarter of 2023 and their performances could hardly look more different.…
Auslandsaktien: „Zweite und dritte Reihe könnte nachziehen“
Die US-Berichtssaison ist in vollem Gange. Für die großen US-Tech-Werte, die „Magnificant Seven“, gibt es eine Menge Vorschusslorbeeren. Unternehmen aus…
3M mit schwachem Ausblick - Auch GE-Ausblick enttäuscht - United Airlines zeigt sich optimistisch
Wien (www.aktiencheck.de) - Johnson & Johnson (ISIN: US4781601046, WKN: 853260, Ticker-Symbol: JNJ, NYSE-Symbol: JNJ) (-1,6%) konnte im Vorjahr mit einem…
Proctor & Gambles Wachstum verlangsamt sich - Johnson & Johnson profitiert von Abspaltung der Konsumgütersparte
Konsumgüterriese Proctor&Gamble wächst weniger stark als erwartet. Johnson & Jonson schließt Geschäftsjahr 2023 stärker als prognostiziert.Im letzten Quartal des Jahres…
J&J’s Spravato success confirms commercial viability of psychedelics for mental health
The commercial success of Johnson & Johnson (NYSE:JNJ)s esketamine nasal spray Spravato for use in treatment-resistant depression and major depressive...…
Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million
The settlement does not resolve the tens of thousands of lawsuits alleging that J&Js talc-based products caused cancer.…
Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript
JNJ earnings call for the period ending December 31, 2023.…
Johnson & Johnson 2023 Q4 - Results - Earnings Call Presentation
…
Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript
…
Johnson & Johnson mit guten Zahlen - Prognose steht
In den USA nimmt die Berichtssaison allmählich an Fahrt auf. Am Dienstag hat auch Johnson & Johnson frische Zahlen zum…
Johnson & Johnson mit guten Zahlen – Prognose steht
In den USA nimmt die Berichtssaison allmählich an Fahrt auf. Am Dienstag hat auch Johnson & Johnson frische Zahlen zum…
Johnson & Johnson undershoots full-year earnings guidance
New Jersey-based pharmaceutical giant Johnson & Johnson (NYSE:JNJ) hit top-line expectations in today’s annual earnings call, but slightly undershot with...…
Johnson & Johnson: MedTech als Wachstumsmotor - Aktienanalyse
Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI),…
Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings
Johnson & Johnson says its on track to meet its 2025 target of $57 billion in pharmaceutical sales.…
Johnson & Johnson in charts: MedTech segment sales surged 13% Y/Y in Q4
…
Johnson & Johnson Q4 earnings beat estimates amid strength in medtech
…
Johnson & Johnson tops revenue estimates, reiterates forecast By Investing.com
Johnson & Johnson tops revenue estimates, reiterates forecast…
Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump
The results come six months after J&J completed its spinoff of consumer health unit Kenvue, the companys biggest shake-up in…
Surgical Dressing Market Valuation to Reach US$1.9 Billion by 2030, Driven by 6.1% CAGR | Persistence Market Research
Discover the dynamic world of the surgical dressing market with a comprehensive market overview. Explore key statistics, technology trends, market…
Earnings week ahead: Tesla, Netflix, AT&T, Johnson & Johnson, GE and more
…
Wochenausblick - Die Quartalssaison steht in den Startlöchern.
WerbungZum Start in die neue Börsenwoche informieren wir jeden Sonntag über Wirtschaftsdaten, Quartalszahlen und mehr. Neben den Quartalszahlen von Netflix,…
Johnson & Johnson wins full FDA approval for bladder cancer therapy Balversa
…
Top 5 Life Science ETFs
Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the…
Johnson & Johnson likely to post dip in 4Q earnings
Johnson & Johnson (NYSE:JNJ) raised its full-year guidance after a strong third quarter which saw earnings beat expectations and its…
Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?
…